Products and Pipeline
At BSS, we’re dedicated to improving lives by expanding access to biologics. Product pipeline with CLEAR IP, DEFINE REGULATORY PATHWAY, KNOW CLINICAL DESIGNED, EVIDENCE OF PATIENT SAFETY with strict adherence to Global Regulatory ( FDA, EMA) Advice
Our robust pipeline is bringing high-value treatments to patients in need. We have the assets, expertise, and insights to bring high-quality products to patients around the world.
Three Oncology Supportive Care biosimilar products, launch in 2022 and 2024
$2.8 Billion combined US addressable market (PEG GCSF, GCSF, DARBO)
$56 Million in development and facility costs subsidized with nearly $40 Million in tax credits and grants - Located in Opportunity Zone
$280 Million cumulative gross revenue in the first full pipeline year (2024)
$2.8 Billion combined US addressable market (PEG GCSF, GCSF, DARBO)
$664 Million cumulative gross revenue first 3 years of market launch (through 2025)